Silica Nanoparticles Erase Prostate Tumors in Mice
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cornell Prime dots (C' dots), ultrasmall core-shell silica nanoparticles already in late-stage clinical trials for image-guided surgery, selectively triggered ferroptosis in aggressive prostate tumors in mice by ferrying iron ions into cancer cells and driving lethal oxidation
- Combination therapy of C' dots plus immune checkpoint blockade produced complete or near-complete remissions in 4 of 10 mice, and adding CSF-1R macrophage-targeting blockade raised complete remissions to 5 of 10 in the preclinical survival study
- Tumor microenvironment shifted from an immune-resistant "cold" state to an active "hot" one, with T cells and macrophages converting from suppressive to cancer-killing states, and no toxicity observed in healthy organs outside brief spleen accumulation
- Targeting was achieved by attaching a molecule that recognizes PSMA, a protein on the surface of prostate tumor cells, ensuring the particles reached prostate cancer specifically
- Lead authors Dr. Michelle Bradbury (radiology) and Dr. Ulrich Wiesner (materials science) led the multi-laboratory collaboration, with co-author Dr. Jedd Wolchok, director of the Parker Institute for Cancer Immunotherapy at Weill Cornell, calling the dual-killing-and-immune-remodeling effect unprecedented
- Publication appeared June 15, 2026 in Cancer Research (DOI: 10.1158/0008-5472.CAN-25-4954), funded by the Department of Defense, the National Cancer Institute, and Parker Institute funding, with human clinical trials as the next stated goal
Why it matters: Prostate cancer has historically been resistant to immunotherapy, with durable responses difficult to achieve — this preclinical study achieves complete remissions in half of treated mice with combination therapy by simultaneously killing tumor cells and unlocking an antitumor immune response, a dual mechanism Bradbury said represents a potential new clinical paradigm if it translates to humans.
